Skip to content
The Policy VaultThe Policy Vault

dupilumab — Blue Cross Blue Shield of Montana

chronic spontaneous urticaria (CSU)

Initial criteria

  • The requested agent is eligible for continuation of therapy when the prescriber states the patient has been treated with the requested agent within the past 90 days and is at risk if therapy is changed.
  • For new starts, the patient must meet ONE of the following: